Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Exclusion Criteria

• •Have a history of prior PDT, external-beam radiation, subfoveal focal laser photocoagulation, submacular surgery, or transpupillary thermotherapy in the study eye
• •Have atrophy under the center of the fovea
• •Have angioid streaks, presumed ocular histoplasmosis syndrome, myopia (greater than 6 diopters), or choroidal neovascularization secondary to other causes than AMD
• •Are receiving or require chronic concomitant therapy with systemic (\> 5 mg) or ocular corticosteroids. Chronic concomitant therapy is defined as multiple doses taken daily for 14 or more consecutive days at any time within 6 months prior to screening
• •Inability to obtain photographs, fluorescein angiography, or optical coherence tomography to document CNV, e.g. due to media opacity, allergy to fluorescein dye or lack of venous access
• •Have received prior treatment with any anti-angiogenic compound or any investigational treatment (e.g. Macugen, Avastin \[bevacizumab\], Ruboxistaurin, Lucentis \[ranibizumab\], Retaane \[anecortave acetate\], squalamine, siRNA, VEGF-Trap etc.) for neovascular AMD
• •Have the presence of fibrosis, hemorrhage, pigment epithelial detachments, tear (rip) of the retinal pigment epithelium or other hypofluorescent lesions obscuring greater than 50% of the CNV lesion
• •Have any additional ocular diseases which have irreversibly compromised or follow-up could likely compromise the visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy, clinically significant diabetic macular edema, severe non-proliferative diabetic retinopathy
• •Within two months prior to screening, have had intraocular surgery (including cataract surgery) in the study eye
• •Within 1 month prior to screening had YAG laser in the study eye
• •Have had previous intravitreal drug delivery (injection or drug device implantation) in the study eye
• •Have had previous pars plana vitrectomy in the study eye
• •Have systemic cancer under active treatment with chemotherapeutic agents
• •Are being treated with anti-coagulants more than 325mg of aspirin per day.
• •Have hepatic insufficiency as defined as an SGOT greater than the upper limit of normal or a total bilirubin 1.5 times the upper limit of normal
• •Have history of congestive heart failure, myocardial infarction, transient ischemic attack and/or stroke within the last 3 months.
• •Are using herbal products such as St.Johns Wort, acetaminophen (Tylenol), eruthromycin, or phenytoin (Dilatin) on a chronic basis